Gvo Asset Management Ltd adds Becton Dickinson and Co (BDX) to its portfolio

Becton Dickinson and Co (BDX) : Gvo Asset Management Ltd added new position in Becton Dickinson and Co during the most recent quarter end. The investment management firm now holds 13,902 shares of Becton Dickinson and Co which is valued at $2,424,509 , the company said in a statement filed on Jul 14, 2016 with the SEC.Becton Dickinson and Co makes up approximately 0.27% of Gvo Asset Management Ltd’s portfolio.

Other Hedge Funds, Including , Community Bank N.a. boosted its stake in BDX in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 4,665 shares of Becton Dickinson and Co which is valued at $813,576. Becton Dickinson and Co makes up approx 0.19% of Community Bank N.a.’s portfolio.Beacon Capital Management reduced its stake in BDX by selling 45 shares or 17.31% in the most recent quarter. The Hedge Fund company now holds 215 shares of BDX which is valued at $37,763.Triangle Securities Wealth Management reduced its stake in BDX by selling 745 shares or 14.81% in the most recent quarter. The Hedge Fund company now holds 4,286 shares of BDX which is valued at $752,793. Becton Dickinson and Co makes up approx 0.55% of Triangle Securities Wealth Management’s portfolio.Kistler-tiffany Companies reduced its stake in BDX by selling 75 shares or 8.06% in the most recent quarter. The Hedge Fund company now holds 855 shares of BDX which is valued at $150,172. Becton Dickinson and Co makes up approx 0.08% of Kistler-tiffany Companies’s portfolio. Pensionfund Sabic sold out all of its stake in BDX during the most recent quarter. The investment firm sold 11,000 shares of BDX which is valued $1,883,310.

Becton Dickinson and Co closed down -0.68 points or -0.39% at $174.4 with 8,76,567 shares getting traded on Monday. Post opening the session at $175.5, the shares hit an intraday low of $173.51 and an intraday high of $176.01 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Becton Dickinson and Co reported $2.18 EPS for the quarter, beating the analyst consensus estimate by $ 0.17 according to the earnings call on May 5, 2016. Analyst had a consensus of $2.01. The company had revenue of $3067.00 million for the quarter, compared to analysts expectations of $3073.41 million. The company’s revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS.

Many Wall Street Analysts have commented on Becton Dickinson and Co. Company shares were Reiterated by RBC Capital Mkts on May 9, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 169 from a previous price target of $153 .

Becton Dickinson and Company is a global medical technology company engaged in the development manufacture and sale of a range of medical supplies devices laboratory equipment and diagnostic products used by healthcare institutions life science researchers clinical laboratories pharmaceutical industry and the general public. The Company operates through two segments: BD Medical and BD Life Sciences. The Company’s Life Sciences segment consists of the BD Diagnostics and BD Biosciences segments. The Company’s BD Medical segment focuses on providing solutions to reduce the spread of infection enhance diabetes treatment and advance drug delivery. The Company’s BD Diagnostics provides products for the safe collection and transport of diagnostics specimens as well as instruments and reagent systems. Its BD Biosciences provide diagnostic and research tools to life science researchers clinical researchers laboratory professionals and clinicians.

Leave a Reply

Becton Dickinson and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Becton Dickinson and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.